Is amiodarone FDA‑approved for the treatment of atrial fibrillation?

Amiodarone FDA Approval Status for Atrial Fibrillation

Amiodarone is NOT FDA-approved for atrial fibrillation treatment—it is only approved for life-threatening ventricular arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia). However, amiodarone is widely used off-label for AF and is strongly recommended by major cardiology guidelines for this indication 1, 2.

The FDA Approval Reality

The FDA label explicitly states that amiodarone is indicated solely for "initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy" 3. The FDA approved amiodarone in December 1985 specifically for atrial fibrillation and prevention of recurrent ventricular tachycardias according to one source 4, but the current official FDA labeling does not list AF as an approved indication 3.

The use of amiodarone for AF conversion and maintenance of sinus rhythm remains off-label 5. This creates a disconnect between regulatory approval and clinical practice guidelines.

Why Guidelines Strongly Recommend It Despite Lack of FDA Approval

For Acute Cardioversion

The 2024 ESC guidelines give amiodarone a Class I recommendation (highest level) for intravenous cardioversion of AF in patients with:

• Severe left ventricular hypertrophy
• Heart failure with reduced ejection fraction (HFrEF)
• Coronary artery disease

The guideline acknowledges there may be a delay in cardioversion compared to other agents 1.

For Long-Term Rhythm Control

Amiodarone receives a Class I recommendation for patients with AF and HFrEF requiring long-term antiarrhythmic therapy, with the critical caveat of careful monitoring for extracardiac toxicity 1.

The 2014 AHA/ACC/HRS guidelines similarly recommend amiodarone for:

• Prophylaxis in high-risk cardiac surgery patients (Class IIa) 2
• Rate control when other measures fail (Class IIa for IV use, Class IIb for oral) 2

Clinical Efficacy Data

Amiodarone demonstrates superior efficacy compared to alternatives. In the SAFE-T trial, median time to AF recurrence was 487 days with amiodarone versus 74 days with sotalol and 6 days with placebo, with spontaneous conversion occurring in 72.1% of amiodarone patients 5.

Critical Safety Considerations

Major Toxicities Requiring Monitoring

Pulmonary toxicity is the most feared complication:

• Early-onset pulmonary injury can occur within days to weeks 3
• ARDS occurred in 2% of patients in clinical trials 3
• Pulmonary fibrosis is a well-recognized complication of long-term use 3
• Monitor FiO₂, SaO₂, and PaO₂ closely 3

Thyroid dysfunction:

• Both hypothyroidism and hyperthyroidism can occur 3
• Amiodarone-induced thyrotoxicosis may cause arrhythmia breakthrough or death 3
• Any new arrhythmia signs should prompt evaluation for hyperthyroidism 3

Optic neuropathy/neuritis:

• Can result in permanent blindness 3
• Requires regular ophthalmic examination including fundoscopy and slit-lamp examination 3

Hepatotoxicity:

• Liver function test abnormalities are common 3

Cardiovascular effects:

• Hypotension (most common reason for discontinuation at 1.6%) 3
• Bradycardia and AV block 3
• QTc prolongation with risk of torsades de pointes 3

Mortality Concerns

Recent data suggests potential mortality risk. In patients with left ventricular hypertrophy, amiodarone was associated with 1.58 times higher mortality risk compared to other antiarrhythmics (HR 1.58,95% CI 1.03-2.44) 6. This challenges the guideline preference for amiodarone in LVH patients, though the study was retrospective.

Practical Clinical Algorithm

For acute AF cardioversion:

1. If structurally normal heart → Use flecainide or propafenone IV (Class I) 1
2. If HFrEF, severe LVH, or CAD → Use amiodarone IV (Class I), accepting delayed conversion 1
3. If recent ACS or severe aortic stenosis → Avoid vernakalant; use amiodarone 1

For long-term rhythm control:

1. If structurally normal heart → Flecainide or propafenone preferred 1
2. If HFrEF → Amiodarone is the recommended choice (Class I) 1
3. If HFmrEF, HFpEF, or valvular disease → Consider dronedarone first 1
4. If other agents fail or contraindicated → Amiodarone with intensive monitoring 1

Mandatory monitoring when using amiodarone:

• Baseline and periodic thyroid function tests
• Baseline and periodic liver function tests
• Baseline and periodic pulmonary function tests and chest X-ray
• Regular ophthalmic examinations
• ECG monitoring for QTc prolongation and bradycardia

Common Pitfalls to Avoid

1. Don't use amiodarone as first-line in structurally normal hearts when safer alternatives (flecainide, propafenone) are available
2. Don't skip baseline testing before initiation—you need baseline thyroid, liver, pulmonary, and eye exams
3. Don't ignore new respiratory symptoms—early pulmonary toxicity can progress to ARDS or death 3
4. Don't combine with other QT-prolonging drugs without careful risk assessment 3
5. Don't use in patients with sinus node dysfunction or AV block unless pacing is available 1

Bottom Line

While amiodarone lacks FDA approval for AF, it remains a guideline-recommended option with Class I evidence for specific patient populations, particularly those with structural heart disease where alternatives are contraindicated. The decision to use amiodarone must weigh its superior antiarrhythmic efficacy against significant toxicity risks requiring intensive monitoring. In structurally normal hearts, use safer alternatives first.